AllianceRx Walgreens Prime to distribute Lundbeck's VyeptiAllianceRx Walgreens Prime will distribute Lundbeck's Vyepti, an intravenous preventive migraine treatment. Survey: Specialty pharmacists report administrative delays to treatmentA Surescripts survey finds that nearly two-thirds of specialty pharmacists report spending more than 15 minutes on the phone to fill one prescription. IQVIA report: Global medicine spending to top $1.1T by 2024 IQVIA reports that global use of medicine has increased at a 3% compound annual growth rate since 2014, slowing from a 4% rate from 2009–2014. Hikma, Glenmark ink licensing agreement for Ryaltris Glenmark and Hikma will commercialize a fixed-dose combination nasal spray for seasonal allergic rhinitis. United Therapeutics, DEKA get FDA OK for subcutaneous delivery system for Remodulin The Remunity system to treat pulmonary arterial hypertension is expected to be available by July for specialty pharmacies. Grifols launches Xembify Grifol’s Xembify is the first 20% subcutaneous immunoglobulin for primary immunodeficiency treatment. Walgreens earns enterprise-wide URAC Specialty Pharmacy accreditation Walgreens has earned the first enterprise-wide URAC Specialty Pharmacy accreditation for its network of more than 300 community specialty pharmacies. OptumRx acquires Diplomat Pharmacy Diplomat and OptumRx's combination will expand the innovative specialty pharmacy and infusion solutions that OptumRx can offer. Diplomat posts Q3 loss along with drop in PBM segment Diplomat's Q3 revenue was comprised of $1.2 billion from the company’s specialty segment and $82 million from its pharmacy benefit manager segment Diplomat sells certain assets of Envoy Health Management to Diligent Health Solutions Diplomat is retaining a portion of the Envoy Health Management operations that specialize in digital therapeutics and pharmaceutical services. First Previous 16 17 18 19 20 Next Last
